HOME >> BIOLOGY >> NEWS
Biodesign and TGen form joint Center for Systems and Computational Biology

To help usher in a new era of molecular diagnostics and personalized medicine, ASU's Biodesign Institute and the Translational Genomics Research Institute (TGen) have teamed up to establish the Center for Systems and Computational Biology.

One of the first of its kind in the nation, the new center will accelerate the pace of biomedical research, directly impact patient care and provide new funding opportunities for both TGen and ASU. George Poste, director of the Biodesign Institute, and Jeffrey Trent, president and scientific director of TGen, will oversee the center. Systems biology is an emerging science that requires highly-integrated efforts between biologists, physicians, chemists, engineers and computer scientists. It combines "wet lab" research with "dry lab" computational technologies to help identify the molecular pathways relevant to disease. The resulting benefits to medicine may include better clinical trials, personalized therapies and improved diagnostics, drugs and vaccines.

"Much of our focus at Biodesign is in trying to understand biological function and the significance of disease at the most fundamental level: its molecular circuitry," said Poste. "This knowledge has enormous implications for every aspect of medicine, as well as other fields of science."

"At TGen, our focus is entirely on developing earlier diagnostics and smarter treatments," said Trent. "This new collaboration leverages the fast-growing field of computational biology to speed research and directly impact patients. Additionally, this partnership opens the door to new research and funding avenues for both TGen and ASU."

Accelerating Research

The Center for Systems and Computational Biology will use the extraordinary power of the ASU-TGen supercomputer to accelerate research by quickly analyzing the billions of data points generated by genetic research. For example, a researcher at a major U.S. university estimated it would take hi
'"/>

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-727-0369
Arizona State University
6-Feb-2006


Page: 1 2 3 4

Related biology news :

1. Biodesign Institute leads innovative project to prevent cancer
2. Biodesign Institute takes part in $14.4M NIH chemical defense grant
3. Biodesign Institute participates in first-of-its-kind coyote disaster preparedness drill
4. Biodesign Institute at ASU named lab of the year in international competition
5. Biodesign Institute awarded $3.2 million to develop vaccine to thwart biothreat
6. Biodesign Institute and TGen awarded grants to help lessen threat of radiological terrorist event
7. New joint replacement material developed at MGH put to first clinical use
8. It takes a village -- female ducks negotiate joint rearing of ducklings
9. Brown and OTS will jointly manage new ILTER network secretariat
10. How movement lubricates bone joints
11. Gene therapy research switches off joint inflammation; switches on genetic process of joint repair

Post Your Comments:
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: